Global Cancer Clinical Decision Tools Market Analysis 2024 , Forecast To 2033
7 Mar, 2024
The cancer clinical decision tools market has also seen rapid expansion, growing from $0.45 billion in 2023 to $0.5 billion in 2024 at a CAGR of 11.2%. This growth is attributed to the increasing prevalence and complexity of cancer, rising demand for personalized medicine, and government support for research and development. Future growth, reaching $0.72 billion in 2028 at a CAGR of 9.6%, will be driven by factors like the global aging population, patient engagement, shared decision-making, and advancements in medical imaging, AI-driven clinical decision support, telemedicine, predictive analytics, and ethical and regulatory considerations.
Global Cancer Clinical Decision Tools Market Key Driver
The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer clinical decision tools market. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. Therefore, the rise in cancer incidence rates across the globe will increase the demand for cancer clinical decision tools to make treatment decisions faster, thereby contributing to the cancer clinical decision tools market growth.
Get A Free Sample Of The Global Cancer Clinical Decision Tools Market ReportGlobal Cancer Clinical Decision Tools Market Segments
The cancer clinical decision tools market covered in this report is segmented –
1) By Type: Risk Assessment Tool(RAT), Qcancer
2) By End-User: Hospital, Clinics
By Geography: The countries covered in the cancer clinical decision tools market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
North America was the largest region in the cancer clinical decision tools market in 2023. The regions covered in the cancer clinical decision tools market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Major Cancer Clinical Decision Tools Industry Players
McKesson Corporation; Medical Information Technology Inc.; Philips Healthcare; Siemens Healthineers AG; Elsevier B.V.; Macmillan Publishers Limited; National Decision Support Company; IBM Watson Health; Cerner Corporation; GE Healthcare; Allscripts Healthcare Solutions Inc.; Epic Systems Corporation; Koninklijke Philips N.V.; RaySearch Laboratories AB; Elekta AB; Varian Medical Systems Inc.; Accuray Incorporated; F. Hoffmann-La Roche Ltd.; Flatiron Health Inc.; Tempus Labs Inc.; NantHealth Inc.; Syapse Inc.; Inspirata Inc.; Oncora Medical Inc.; Prognos Health Inc.; Deep 6 AI Inc.; PathAI Inc.; Enlitic Inc.; Ibex Medical Analytics Ltd.; Zebra Medical Vision Ltd.; Aidoc Medical Ltd.
Get The Full Global Cancer Clinical Decision Tools Market Report
Cancer Clinical Decision Tools Market Overview
Cancer clinical decision tools refer to the tools that are developed to help medical practitioners identify suspected cancer signs and symptoms and treat patients effectively. These tools aid in clinical decision-making by assisting GPs in deciding whether to refer or seek additional diagnostic testing in patients suspected of having cancer.